Research Institute: Queensland Brain Institute
Amount granted: $1.14 million
Year granted: 2005
The ACRF grant allowed for the building of an integrated Brain Tumour Flow Cytometry Screening Facility is based at the Queensland Brain Institute, University of Queensland. The facility was built around the latest in flow cytometry technology, allowing processing and analysis of large numbers of samples to characterise and build phenotypes of glioma.
Funding provided by ACRF was specifically directed towards the purchase of state-of-the-art equipment for the new facility. The Brain Tumour Flow Cytometry Screening Facility was afforded dedicated self-contained laboratory space within the new Queensland Brain Institute building, which was completed in mid-2007.
The overall goal of this project was to establish the world’s first automated high throughput screening facility focused on functional cell-based analysis and identification of stem cells derived from human brain tumours. Successful application of this technology significantly advances the discovery process for identifying molecules that specifically target tumour-inducing stem cells in the central nervous system and the anticipation that the technology will ultimately find application to other solid tissue cancers including breast, skin and prostate.
Director of Research: Professor Perry F Bartlett FAA, Program Leader Chief Investigators: Professor Andrew Boyd PhD, Assistant Director and Head of Cancer and Cell Biology, Queensland Institute of Medical Research, Professor Brandon J Wainwright PhD, Institute for Molecular Bioscience, Queensland and Professor Brent A Reynolds PhD, Senior Research Fellow, Queensland Brain Institute
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.